Myriad Genetics, Inc. has grown revenue 4.9% a year over three years and 4.0% a year over five. Revenue growth, 3-year annual rate: +4.9% (Diagnostics & Research median +8.4%). Revenue growth, 5-year rate: +4.0%, growth has picked up over the last three years. Years of annual history on file: 17, FY2009 to FY2026, as filed.

MYGNMyriad Genetics, Inc.

Healthcare

$4.18-45% 1Y

$4.18

$2.8752 weeks$8.18

Is it growing?

Mixed

Neither accelerating nor breaking down: operating margin widening (+36.9 points), but revenue shrinking (−3% year on year).

1 good, 1 to watch, 1 without data

Revenue trend−3% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +4% a year.

Margin direction+36.9 points operating

Trailing-twelve-month operating margin, -12.4% now against -49.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is MYGN growing?

Myriad Genetics, Inc. has grown revenue 4.9% a year over three years and 4.0% a year over five.

+4.9%

Revenue growth, 3-year annual rate · Diagnostics & Research median +8.4% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +4.0%
Revenue growth, 5-year rate · +4.9% over three · growth has picked up over the last three years
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2026, as filed

Details›